Antipsychotics, Newer Isn’t BetterDrug_Washington Post front page
“a study published yesterday overturns conventional wisdom about antipsychotic drugs, which cost the United States $10 billion a year.”
“a study published yesterday overturns conventional wisdom about antipsychotic drugs, which cost the United States $10 billion a year.”
Dr. Sanghavi provides us with a statistical reality-check by which to gauge for ourselves whether or not we should–or need not–take a octor’s advice about starting a medical treatment for a speculated risk–rather than evidence of illness.
Success in academic psychiatry is not measured in the improvement of patients' mental health, but rather in quantifiable commercial tender.How many grants one brings to the university, how many publications one churns out each year, and how many corporate and professional advisory boards one serves on–and how much money one…
"This is really an ethical Potemkin village, where a hollow system appears to provide the illusion of integrity, but transgressors never leave."
Stanford University announced that it is adopting a strict conflicts of interest policy.
AIR: America’s Investigative Reports, is a new Public Broadcasting System (PBS) series whose first report, "A Bitter Pill," airs Friday, Sept. 8.
Psychiatry’s most powerful and influential key opinion leaders who belong to the American College of Neuropsychopharmacology (ACNP) have been caught off guard. The ACNP leadership is scrambling to overcome the scorn it has received following public disclosure about multiple breaches of ethics and professional standards of conduct. The College and…
Suicide rates fluctuate. Like the stock market their rise and fall is not due to a single decisive cause, but rather to a confluence of complex factors.
Steven Potkin, who, LAT reports, is a brother-in-law of Jane Pauley who wrapped up her career as TV news anchor to become a paid drug pusher.
New Peer-Reviewed Publication Authored By Leading Scientists Provides Comprehensive Review of VNS Therapy Mechanism of Action in Treatment-Resistant Depression
Two probing first rate investigative reports document how psychiatry’s treatments are shaped by "opinion leaders" whose professional recommendations are compromised by their substantial, largely undisclosed, financial ties to drug companies.
An investigative report in Mercury News (below) focuses on Stanford University department heads, associate deans and other leaders because “these are senior people who set the tone at the medical school and are role models for junior faculty members.”